title: [Basic and clinical evaluation of an immunoradiometric competitive inhibition assay for 2----6 sialyl Lewis a antigen--2. Evaluation of clinical significance].
abstract: The clinical significance of serum 2----6 sialyl Lewisa antigen was evaluated using "SLA 2----6 Otsuka" kits. Results indicated that the antigen was frequently elevated in sera obtained from patients with various cancers, including pancreas (73%), liver (67%), bilialy tract (66%), uterus (35%), and stomach (33%). Among other tumor markers examined, CA 19-9 (2----3 sialyl Lewisa) had a very similar cancer spectrum as 2----6 sialyl Lewisa. In the sera of patients with malignant disorders of digestive and respiratory organs, including stomach, intestine, pancreas, biliary tract and lung, the serum levels of CA19-9 tended to be higher than those of 2----6 sialyl Lewisa, usually exceeded those of CA19-9. This suggests that the 2----6 sialylation of Lewisa antigen is equally observed in malignant and non-malignant diseases, while the 2----3 sialylation is relatively specific to cancers. As a result, the ratio of the two antigens, CA 19-9: 2----6 sialyl Lewisa antigen ratio, exceeded 2.0 in most of the sera obtained from patients with malignancy, whereas the ratio was below 2.0 in most of patients with corresponding non-malignant diseases of those organs. The determination of the ratio may be clinically useful in the differential diagnosis of the malignant and non-malignant diseases in those organs.
authors.affiliation: 2nd Dept. of Internal Medicine, Faculty of Medicine, Kyoto University.
authors.forename: H
authors.initials: H
authors.lastname: Imura
authors.forename: T
authors.initials: T
authors.lastname: Takahashi
authors.forename: T
authors.initials: T
authors.lastname: Matsuda
authors.forename: O
authors.initials: O
authors.lastname: Yoshida
authors.forename: H
authors.initials: H
authors.lastname: Ohkura
authors.forename: Y
authors.initials: Y
authors.lastname: Seitetsu
authors.forename: Y
authors.initials: Y
authors.lastname: Seino
authors.forename: M
authors.initials: M
authors.lastname: Ishii
authors.forename: M
authors.initials: M
authors.lastname: Kuwabara
authors.forename: Y
authors.initials: Y
authors.lastname: Ariyoshi
mesh_terms: D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm / Q000032:analysis*; D015295:Antigens, Tumor-Associated, Carbohydrate / Q000032:analysis; D001667:Binding, Competitive; D014408:Biomarkers, Tumor / Q000097:blood*; D005260:Female; D006801:Humans; D007564:Japan; D007983:Lewis Blood Group Antigens / Q000032:analysis*; D008297:Male; D015337:Multicenter Studies as Topic; D009369:Neoplasms / Q000175:diagnosis* / Q000276:immunology / Q000473:pathology; D011237:Predictive Value of Tests; D011863:Radioimmunoassay / Q000379:methods
chemical_list: D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm; D015295:Antigens, Tumor-Associated, Carbohydrate; D014408:Biomarkers, Tumor; D007983:Lewis Blood Group Antigens